ZA200810863B - Humanized anti-human osteopontin antibody - Google Patents

Humanized anti-human osteopontin antibody

Info

Publication number
ZA200810863B
ZA200810863B ZA200810863A ZA200810863A ZA200810863B ZA 200810863 B ZA200810863 B ZA 200810863B ZA 200810863 A ZA200810863 A ZA 200810863A ZA 200810863 A ZA200810863 A ZA 200810863A ZA 200810863 B ZA200810863 B ZA 200810863B
Authority
ZA
South Africa
Prior art keywords
human osteopontin
humanized anti
osteopontin antibody
antibody
human
Prior art date
Application number
ZA200810863A
Other languages
English (en)
Inventor
Nobuchika Yamamoto
Fumihiko Sakai
Hirofumi Higuchi
Masaharu Torikai
Toshihiro Nakashima
Original Assignee
Astellas Pharma Inc
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Chemo Sero Therapeut Res Inst filed Critical Astellas Pharma Inc
Publication of ZA200810863B publication Critical patent/ZA200810863B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200810863A 2006-05-31 2008-12-23 Humanized anti-human osteopontin antibody ZA200810863B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006152892 2006-05-31

Publications (1)

Publication Number Publication Date
ZA200810863B true ZA200810863B (en) 2010-08-25

Family

ID=38778682

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810863A ZA200810863B (en) 2006-05-31 2008-12-23 Humanized anti-human osteopontin antibody

Country Status (17)

Country Link
US (1) US7807161B2 (fr)
EP (1) EP2025749B8 (fr)
JP (1) JP4064441B2 (fr)
KR (1) KR20090024748A (fr)
CN (1) CN101495632B (fr)
AT (1) ATE553130T1 (fr)
AU (1) AU2007268591A1 (fr)
BR (1) BRPI0711229A2 (fr)
CA (1) CA2653661A1 (fr)
ES (1) ES2384350T3 (fr)
IL (1) IL195503A0 (fr)
MX (1) MX2008015309A (fr)
NO (1) NO20085282L (fr)
RU (1) RU2429016C2 (fr)
TW (1) TW200813087A (fr)
WO (1) WO2007139164A1 (fr)
ZA (1) ZA200810863B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2503720C2 (ru) 2008-01-11 2014-01-10 Астеллас Фарма Инк. УЛУЧШЕННОЕ ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ α9-ИНТЕГРИНУ
JP5339748B2 (ja) * 2008-03-11 2013-11-13 国立大学法人北海道大学 ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
JP5736176B2 (ja) * 2008-04-24 2015-06-17 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに特異的なヒト化抗体およびその使用
JP5765814B6 (ja) 2009-10-21 2018-06-27 国立大学法人広島大学 インテグリンα８β１特異的モノクローナル抗体
WO2012050646A2 (fr) 2010-06-29 2012-04-19 The Trustees Of The University Of Pennsylvania Capteurs chimiques biomimétiques employant un affichage nanoélectronique de récepteurs olfactifs
US10983117B2 (en) * 2011-08-31 2021-04-20 The Trustees Of The University Of Pennsylvania Carbon nanotube biosensors and related methods
WO2014061783A1 (fr) 2012-10-19 2014-04-24 株式会社イーベック Anticorps humain spécifique d'une toxine produite à partir de clostridium difficile, ou fragment de liaison à un antigène correspondant
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US11415546B2 (en) 2014-09-05 2022-08-16 The Trustees Of The University Of Pennsylvania Volatile organic compound-based diagnostic systems and methods
CN109477525A (zh) 2016-07-06 2019-03-15 德纳汽车系统集团有限责任公司 车桥和驱动轴的快速连接接头附连组件
KR20180000875U (ko) 2016-09-21 2018-03-29 전은희 조명 모듈
WO2018119142A1 (fr) 2016-12-21 2018-06-28 Amgen Inc. Formulations d'anticorps anti-tnf alpha
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
US20230272058A1 (en) * 2021-07-02 2023-08-31 Washington University Compositions and methods for preventing acute kidney injury-induced acute lung injury (aki-ali)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
KR100337069B1 (ko) 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
WO1998002462A1 (fr) * 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Domaines de la superfamille des immunoglobulines et fragments presentant une solubilite accrue
US20040234524A1 (en) * 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
EP1406931A2 (fr) 2001-07-19 2004-04-14 Universität Zürich Modification de domaines humains variables
US7241873B2 (en) * 2001-09-25 2007-07-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-osteopontin antibody and use thereof
US7456260B2 (en) * 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
WO2004103403A1 (fr) 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. Inhibiteur d'activation cellulaire immunocompetente et son utilisation
AU2004324192A1 (en) 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
JP2006152892A (ja) 2004-11-29 2006-06-15 Anest Iwata Corp 気体吸排機械
JP5142707B2 (ja) * 2005-02-08 2013-02-13 一般財団法人化学及血清療法研究所 抗体の改良方法

Also Published As

Publication number Publication date
CA2653661A1 (fr) 2007-12-06
TW200813087A (en) 2008-03-16
IL195503A0 (en) 2011-08-01
NO20085282L (no) 2009-02-26
JP2008005836A (ja) 2008-01-17
JP4064441B2 (ja) 2008-03-19
EP2025749A1 (fr) 2009-02-18
CN101495632B (zh) 2011-08-03
KR20090024748A (ko) 2009-03-09
BRPI0711229A2 (pt) 2013-01-08
US20090053212A1 (en) 2009-02-26
EP2025749B8 (fr) 2012-05-23
US7807161B2 (en) 2010-10-05
ES2384350T3 (es) 2012-07-04
RU2008152769A (ru) 2010-07-20
WO2007139164A1 (fr) 2007-12-06
AU2007268591A1 (en) 2007-12-06
RU2429016C2 (ru) 2011-09-20
CN101495632A (zh) 2009-07-29
ATE553130T1 (de) 2012-04-15
EP2025749B1 (fr) 2012-04-11
EP2025749A4 (fr) 2009-12-16
MX2008015309A (es) 2009-03-02

Similar Documents

Publication Publication Date Title
ZA200810863B (en) Humanized anti-human osteopontin antibody
EP2418224A3 (fr) Réduction du risque d'anticorps humains et anti-humains par manipulation du gène V
ATE535545T1 (de) Chimäre und humanisierte monoklonale antikörper gegen interleukin-13
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
HRP20181218T1 (hr) Humanizirana anti-il-6 protutijela, pripravci, postupci pripreme i upotrebe
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2007129895A3 (fr) Anticorps monoclonal antagoniste anti-cd40 humain
ATE520716T1 (de) Humanisierter anti-cd4-antikörper mit immunsuppressiven eigenschaften
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
NZ585622A (en) Hepatitis c virus antibodies
ATE512986T1 (de) Antikörper gegen clostridium difficile-toxine und ihre verwendung
EA200901500A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
DK3332808T3 (da) Humaniserede L243-antistoffer
BRPI0821211A2 (pt) Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.
ZA200706036B (en) Anti-IL-12 antibodies, epitopes, compositions, methods and uses
WO2003078600A3 (fr) Anticorps monoclonaux humains diriges contre la proteine m2 du virus de la grippe et methodes de production et d'utilisation de ceux-ci
WO2007087289A3 (fr) ANTICORPS ANTI-FcRn UTILISÉS DANS LE TRAITEMENT D'ÉTATS AUTO/ALLO-IMMUNS
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
WO2011112850A3 (fr) Anticorps anti-properdine humanisés et chimériques
WO2008094942A8 (fr) Anticorps humanisés contre cxcr3
MX2008002161A (es) Anticuerpos quimericos con regiones de primate del nuevo mundo.
DK1907854T3 (da) Monoklonale antistoffer, hybridomcellelinjer, fremgangsmåder og kits til detektion af phytase
BRPI0509495A2 (pt) anticorpo humanizado
WO2006001965A3 (fr) Reduction du risque d'anticorps anti-humains humains par manipulation du gene v
PT1718678T (pt) Anticorpo monoclonal de tenascina anti-humano